ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

18,487Medicare Part D Prescriptions Filled, Including Refills

Rank: 18 out of 1448

$1.95M Total Retail Price of All Prescriptions

Rank: 10 out of 1448

916 Patients Receiving at Least One Drug in Part D
97%Patients 65 Years and Older
72% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

1% of this provider’s 916 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

1% of this provider’s 18,111 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

48% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$105 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 12.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
AMLODIPINE BESYLATE 1,154 1,138 1 2
ATORVASTATIN CALCIUM 993 977 2 4
CRESTOR 860 853 3 17
SIMVASTATIN 668 657 4 3
LOSARTAN POTASSIUM 639 625 5 11
ZETIA 585 553 6 28
CARVEDILOL 473 451 7 1
METOPROLOL SUCCINATE 445 443 8 6
BYSTOLIC 436 423 9 32
FUROSEMIDE 420 416 10 7
SOTALOL 374 363 11 40
WARFARIN SODIUM 336 324 12 8
TAMSULOSIN HCL 327 327 13 46
NEXIUM 319 305 14 49
MULTAQ 311 309 10 15 57
LOSARTAN-HYDROCHLOROTHIAZIDE 306 302 16 38
CLOPIDOGREL 296 284 17 10
ALLOPURINOL 291 278 18 43
DIOVAN 290 274 19 15
POTASSIUM CHLORIDE 277 274 20 19
PLAVIX 274 269 21 14
ATENOLOL 249 247 22 12
LIPITOR 245 243 23 30
PRADAXA 235 235 24 27
METFORMIN HCL 234 230 25 25
LEVOTHYROXINE SODIUM 225 217 26 21
ZOLPIDEM TARTRATE 225 225 26 34
JANUVIA 216 213 28 64
OMEPRAZOLE 203 203 29 23
DIGOXIN 196 196 30 13
ALENDRONATE SODIUM 192 192 31 41
LOVAZA 191 176 32 39
AVODART 184 184 33 120
ISOSORBIDE MONONITRATE ER 151 145 34 16
SPIRONOLACTONE 143 143 35 24
SINGULAIR 127 127 36 91
VYTORIN 125 124 37 71
FINASTERIDE 118 118 38 141
LIVALO 114 99 39 154
FAMOTIDINE 113 113 40 60
REVATIO 111 111 41 248
KLOR-CON 8 110 109 42 70
PRAVASTATIN SODIUM 105 90 43 20
XARELTO 103 103 44 58
RANEXA 102 102 45 37
DIOVAN HCT 93 91 46 29
ADVAIR DISKUS 88 88 47 74
CELEBREX 85 85 48 77
PANTOPRAZOLE SODIUM 83 83 49 42
BENICAR 82 82 50 50
WELCHOL 82 81 50 103
MONTELUKAST SODIUM 81 81 52 135
AMIODARONE HCL 79 79 53 22
AZITHROMYCIN 79 79 53 76
JANUMET 74 74 55 119
NAMENDA 73 73 56 93
GLIMEPIRIDE 71 71 57 66
METOPROLOL TARTRATE 70 70 58 9
EFFIENT 70 70 58 69
SERTRALINE HCL 67 67 60 99
DONEPEZIL HCL 67 67 60 68
TERAZOSIN HCL 67 67 60 116
ACTOS 67 67 60 92
RAMIPRIL 65 65 64 36
JALYN 65 65 64 296
TRAZODONE HCL 64 64 66 128
SPIRIVA 61 61 67 97
HYDROCODONE-ACETAMINOPHEN 58 58 S3 68 33
NIASPAN 57 53 69 47
NITROSTAT 53 52 70 31
NITROGLYCERIN PATCH 51 51 71 98
PROPRANOLOL HCL 51 42 71 105
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 23, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.